Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Br.Mn.4H2O |
| Molecular Weight | 286.807 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[Mn++].[Br-].[Br-]
InChI
InChIKey=HHDPJRSXPOGIOP-UHFFFAOYSA-L
InChI=1S/2BrH.Mn.4H2O/h2*1H;;4*1H2/q;;+2;;;;/p-2
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Mn |
| Molecular Weight | 54.938 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.alfa.com/en/catalog/032808/https://www.ncbi.nlm.nih.gov/pubmed/6658791https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://google.com/patents/CN104529454A?http://pubs.acs.org/doi/pdfplus/10.1021/jo970656jhttps://www.drugs.com/pro/manganese-sulfate-injection.htmlhttp://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367Curator's Comment: description was created based on several sources, including
https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm
Sources: https://www.alfa.com/en/catalog/032808/https://www.ncbi.nlm.nih.gov/pubmed/6658791https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://google.com/patents/CN104529454A?http://pubs.acs.org/doi/pdfplus/10.1021/jo970656jhttps://www.drugs.com/pro/manganese-sulfate-injection.htmlhttp://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367
Curator's Comment: description was created based on several sources, including
https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm
Manganese citrate is generally recognized as safe direct food additive. Manganese citrate complex has being used in the determination of liver enzyme activities in the aging process and following treatment with aminoethylisothiuronium bromide hydrobromide (AET).
Originator
Sources: https://www.americanelements.com/manganese-ii-iodide-7790-33-2https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19610920&CC=GB&NR=877677A&KC=Ahttp://www.newworldencyclopedia.org/entry/Manganese
Curator's Comment: Manganese was first discovered by Torbern Olof Bergman in 1770 and first isolated by Johann Gottlieb Gahn in 1774.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1075097 |
|||
Target ID: CHEMBL1795148 |
|||
Target ID: CHEMBL4612 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseManganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese. |
|||
| Primary | Unknown Approved UseManganese is used for weak bones (osteoporosis). |
|||
| Palliative | Unknown Approved UseEarly research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension. |
|||
| Curative | MANGANESE SULFATE Approved UseManganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
|||
| Primary | MANGANESE SULFATE Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cytochrome oxidase determination using a manganese citrate complex. | 1970 |
|
| Effect of quantity and route of administration of manganese monoxide on feed intake and serum manganese in ruminants. | 1985 Feb |
|
| Manganese citrate improves base-calling accuracy in DNA sequencing reactions using rhodamine-based fluorescent dye-terminators. | 1999 Mar 1 |
|
| Manganese citrate chemistry: syntheses, spectroscopic studies, and structural characterizations of novel mononuclear, water-soluble manganese citrate complexes. | 2000 Sep 4 |
|
| Differential ability of transition metals to induce pulmonary inflammation. | 2001 Nov 15 |
|
| Is the axial zero-field splitting parameter of tetragonally elongated high-spin manganese(III) complexes always negative? | 2002 Jul 31 |
|
| Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin. | 2003 Jan |
|
| Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. | 2005 Mar |
|
| Persistent alterations in biomarkers of oxidative stress resulting from combined in utero and neonatal manganese inhalation. | 2005 May |
|
| Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. | 2009 Sep |
|
| Expression profile analysis of antioxidative stress and developmental pathway genes in the manganese-exposed intertidal copepod Tigriopus japonicus with 6K oligochip. | 2013 Aug |
|
| Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters as Used in Cosmetics. | 2014 May |
|
| Controlled Synthesis of Hollow Manganese Oxide Nanocrystals. | 2016 Feb |
|
| Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats. | 2016 Nov |
Patents
Sample Use Guides
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:55:59 UTC 2023
by
admin
on
Fri Dec 15 18:55:59 UTC 2023
|
| Record UNII |
8308V6RBJ5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10031-20-6
Created by
admin on Fri Dec 15 18:55:59 UTC 2023 , Edited by admin on Fri Dec 15 18:55:59 UTC 2023
|
PRIMARY | |||
|
19915385
Created by
admin on Fri Dec 15 18:55:59 UTC 2023 , Edited by admin on Fri Dec 15 18:55:59 UTC 2023
|
PRIMARY | |||
|
DTXSID00143128
Created by
admin on Fri Dec 15 18:55:59 UTC 2023 , Edited by admin on Fri Dec 15 18:55:59 UTC 2023
|
PRIMARY | |||
|
8308V6RBJ5
Created by
admin on Fri Dec 15 18:55:59 UTC 2023 , Edited by admin on Fri Dec 15 18:55:59 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
